Consequently, to activate the STING pathway to enhance the efficiency of ICB therapy, the application of NRF2 inhibitors or STING agonists in the ICB therapy of KK tumors will provide a new strategy for NSCLC treatment. The gene discussed is STING1; the disease is non-small cell lung carcinoma.